HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS: A SEER-MEDICARE ANALYSIS

被引：0
|
作者：
Stein, E. M. [1 ]
Latremouille-Viau, D. [2 ]
Shi, S. [2 ]
Guerin, A. [2 ]
Wu, E. [3 ]
Bonifacio, G. [4 ]
Cao, X. [4 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Anal Grp Inc, Montreal, PQ, Canada
[3] Anal Grp Inc, Boston, MA USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG20
引用
收藏
页码：S132 / S133
页数：2
相关论文
共 50 条
  • [21] Evaluation of Bleeding and Thrombocytopenia in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review
    Yang, Jiayu
    Choi, Nora
    Paulson, Kristjan
    Sanford, David
    Mozessohn, Lee
    Houston, Donald S.
    Rimmer, Emily
    Lother, Sylvain
    Mendelson, Asher
    Garland, Allan
    Buckstein, Rena
    Hay, Annette E.
    Zarychanski, Ryan
    Houston, Brett L.
    BLOOD, 2022, 140 : 12315 - 12316
  • [22] Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents
    Roberts, Daniel A.
    Steensma, David P.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2015, 10 (03) : 318 - 328
  • [23] Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents
    Daniel A. Roberts
    David P. Steensma
    Current Hematologic Malignancy Reports, 2015, 10 : 318 - 328
  • [24] The Effects of Hypomethylating Agents on Mutational Profiles in Patients with Myelodysplastic Syndromes
    Qiu, Jihui
    Velu, Priya
    Rosenbaum, Jason
    Babushok, Daria
    Bagg, Adam
    MODERN PATHOLOGY, 2019, 32
  • [25] The Effects of Hypomethylating Agents on Mutational Profiles in Patients with Myelodysplastic Syndromes
    Qiu, Jihui
    Velu, Priya
    Rosenbaum, Jason
    Babushok, Daria
    Bagg, Adam
    LABORATORY INVESTIGATION, 2019, 99
  • [26] Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
    Jabbour, Elias
    Strati, Paolo
    Cabrero, Monica
    O'Brien, Susan
    Ravandi, Farhad
    Bueso-Ramos, Carlos
    Wei, Qiao
    Hu, Jianhua
    Abi Aad, Simon
    Short, Nicholas J.
    Dinardo, Courtney
    Daver, Naval
    Kadia, Tapan
    Wierda, William
    Wei, Yue
    Colla, Simona
    Borthakur, Gautam
    Cortes, Jorge
    Estrov, Zeev
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (04) : 351 - 358
  • [27] Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: An Analysis of SEER-Medicare Database
    Parikh, Neehar D.
    Marshall, Vincent D.
    Nathan, Hari
    Balkrishnan, Rajesh
    Shahinian, Vahakn
    HEPATOLOGY, 2015, 62 : 409A - 410A
  • [28] Healthcare costs and resource utilization associated with renal cell carcinoma among older Americans: A longitudinal case-control study using the SEER-Medicare data
    Bhandari, Naleen Raj
    Kale, Hrishikesh P.
    Carroll, Norman, V
    McAdam-Marx, Carrie
    Ounpraseuth, Songthip T.
    Tilford, J. Mick
    Kamel, Mohamed H.
    Kent, Erin E.
    Payakachat, Nalin
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (07) : 347.e17 - 347.e27
  • [29] ECONOMIC BURDEN AND HEALTHCARE RESOURCE USE IN MEDICARE BENEFICIARIES WITH MYELODYSPLASTIC SYNDROMES
    Nair, A.
    Buser, H.
    Kohen, Y.
    Delise, B.
    Ricci, J. F.
    Li, J.
    VALUE IN HEALTH, 2023, 26 (06) : S178 - S178
  • [30] Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis
    Ailawadhi, Sikander
    Frank, Ryan D.
    Advani, Pooja
    Swaika, Abhisek
    Temkit, M'hamed
    Menghani, Richa
    Sharma, Mayank
    Meghji, Zahara
    Paulus, Shumail
    Khera, Nandita
    Hashmi, Shahrukh K.
    Paulus, Aneel
    Kakar, Tanya S.
    Hodge, David O.
    Colibaseanu, Dorin T.
    Vizzini, Michael R.
    Roy, Vivek
    Colon-Otero, Gerardo
    Chanan-Khan, Asher A.
    CANCER MEDICINE, 2017, 6 (12): : 2876 - 2885
12345